Share ownership Protalix BioTherapeutics, Inc.

PLX

US74365A3095

Pharmaceuticals

Market Closed - NYSE 16:00:00 2026-09-24 EDT			5-day change	1st Jan Change
2.750 ^USD	-1.79%		+1.85%	+52.78%

09-16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Share class: Protalix BioTherapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	80,571,642	77,447,238 ( 96.12 %)	0	96.12 %

Major shareholders: Protalix BioTherapeutics, Inc.

Name	Stocks	%	Valuation
BlackRock Advisors LLC 4.761 %	3,836,273	4.761 %	10 M $
Dror Bashan 3.144 %	2,532,934	3.144 %	7 M $
Renaissance Technologies LLC 1.36 %	1,096,000	1.36 %	3 M $
STATE STREET CORPORATION 1.221 %	983,582	1.221 %	3 M $
Geode Capital Management LLC 1.216 %	979,995	1.216 %	3 M $
Northern Trust Global Investments Ltd. 1.144 %	922,093	1.144 %	2 M $
Vanguard Portfolio Management LLC 0.6338 %	510,639	0.6338 %	1 M $
Stratos Wealth Partners Ltd. 0.6206 %	500,000	0.6206 %	1 M $
IBI Mutual Funds Management (1978) Ltd. 0.5975 %	481,434	0.5975 %	1 M $
Goldman Sachs Asset Management LP 0.5907 %	475,922	0.5907 %	1 M $
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	17.1%
Individuals	3.88%
State Street Corp.	1.22%
Others	0.94%
Governments	0.07%
Phoenix Financial Ltd.	0.05%
Unknown	76.74%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	15.25%
Individuals	3.88%
United Kingdom	2.04%
Israel	1.08%
Australia	0.56%
Canada	0.24%
Spain	0.08%
France	0.06%
Ireland	0.05%
Netherlands	0.02%

Based on 1000 largest holdings

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Employees

226

Sector

Pharmaceuticals

More about the company